Background and Objective: In silico prediction of drug-target interactions (DTI) could provide valuable information and speed-up the process of drug repositioning -finding novel usage for existing drugs. In our work, we focus on machine learning algorithms supporting drug-centric repositioning approach, which aims to find novel usage for existing or abandoned drugs. We aim at proposing a per-drug ranking-based method, which reflects the needs of drug-centric repositioning research better than conventional drug-target prediction approaches.
Introduction
Pharmaceutical science is an interdisciplinary research area comprising the findings from biology, chemistry, physics and informatics, with drug discovery being its main objective.
One of the key steps in the process of drug discovery is to identify interactions between drugs and targets. Although the existence of interactions can be reliably confirmed by in vitro binding assays (e.g., [1] [2] [3] [4] ), such methods are still expensive in terms of both time and monetary value [5] . Therefore, in silico methods (i.e., virtual screening) can be applied to predict possible DTIs and the most promising candidates can be verified experimentally [6] [7] [8] [9] [10] instead of performing an exhaustive in vitro search of novel interactions. Such approach is highly valuable in various scenarios such as developing drugs for rare diseases [11] , repurposing off-patent drugs [12] or drugs failed in clinical trials [13] and can significantly reduce the cost of introducing novel drugs to the market [14] .
There are two major classes of in silico prediction methods: docking simulations and machine learning methods. Docking simulations (e.g., [6] [7] [8] 10, 15, 16] ) leverage the 3D structure of targets in order to identify potential binding sites of the compounds. Docking simulations are biologically well-accepted but time consuming and require 3D structures of targets. Furthermore, some researchers report that standard molecular docking scoring functions may be replaced by machine learning based scoring functions with improved prediction results [17, 18] .
Machine learning methods in general leverage features based on the structure of drugs and targets (e.g., [9, [19] [20] [21] ), drugs' side-effects [22] , and the knowledge of already confirmed DTIs [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . In particular, in case of Bipartite Local Models (BLM) [23] and its extensions (e.g. [25] , [32] ), prediction of each DTI is based on the neighborhood of involved drug and target. Xia et al. [26] proposed a semi-supervised approach based on Laplacian regularized least square method (RLS) with kernels derived from known DTIs (NetLapRLS). Van Laarhoven et al. [27] proposed to use regularized least squares with Gaussian interaction profile kernel (GIP). The method was later improved by incorporating weighted nearest neighbors to be able to predict interactions also for new drugs and targets (WNN-GIP) [28] .
Another line of research focused on developing matrix factorization techniques for DTI prediction. The core idea is to map both drugs and targets into a shared low-dimensional latent feature space and to use this representation to calculate the probability of drug-target interactions. Matrix factorization techniques differ from one another especially in the optimization criteria, the choice of iterative optimization method and the exact inference of DTI probability. In particular, Gönen [29] proposed a kernelized Bayesian matrix factorization (KBMF) method. KBMF utilizes drugs' and targets' similarity kernels , , decomposes original DTI matrix as ≈ and thus considers drugs' and targets' similarity in DTI prediction. Zheng et al. [30] proposed the multiple similarities one-class matrix factorization (MSCMF) model with additive regularization based on multiple drug and target similarity matrices. Liu et al. [31] proposed neighborhood regularized logistic matrix factorization (NRLMF), with similar regularization terms as in MSCMF, however the similarity matrices were reduced via the nearest neighbor approach.
Previously mentioned approaches focused on predicting the probability of interactions between all unknown drug-target pairs. Another alternative is to order unknown targets for each drug separately according to the expected interaction probability. We will further denote it as per-drug ranking. Although, for the first sight, the difference might appear to be minor, it affects both the evaluation protocol as well as the internal model of prediction methods, such as the optimization criteria of matrix factorization. Per-drug ranking approach is in accordance with drug-centric repurposing approach as described e.g. by Liu et al. [33] . Drug-centric repurposing approach is based on discovering new interactions for an existing drug d (especially for drugs demonstrated to be safe in Phase I clinical trials, but failed in subsequent Phase II and III trials). In such cases, only the ranking of interactions with d are relevant. For similar tasks, several methods were proposed in the personalized ranking domain, such as BPR [34] or RankALS [35] .
In this paper, we develop a DTI prediction model based on the Bayesian Personalized
Ranking matrix factorization (BPR) [34] . BPR was designed to solve a ranking problem with positive-only information, which is a key challenge in the DTI prediction problem.
However, other relevant circumstances of DTI prediction are not taken into account by BPR. Therefore, we extended BPR to comply with the DTI prediction setting. In particular, the proposed BRDTI is able to handle the case of new drugs and takes chemical and genetic similarities of drugs and targets and target bias into account. Note that, although we focus on the drug-centric approach, after appropriate modifications BRDTI can be utilized for disease-centric repurposing scenarios as well. To the best of our knowledge, this is the first approach to utilize a matrix factorization technique from the personalized ranking domain for DTI prediction and to evaluate the predicted DTIs with respect to the drug-centric repurposing scenario.
The main contributions of this paper are:
-BRDTI method for prediction of DTIs.
We evaluate predictions both in terms of AUC and per-drug normalized discounted cumulative gain (nDCG). As we will discuss, the per-drug nDCG reflects the requirements of drug-centric approach for drug repositioning better than the widelyused AUC. 
Materials and Methods

Materials
To evaluate the proposed methods, we use five benchmark datasets: G-Protein Coupled
Receptors (GPCR), Ion Channels (IC), Nuclear Receptors (NR) and Enzymes (E) datasets originally published by Yamanishi et al. [24] and the Kinase (K) dataset [36] . Each of the first four datasets contains a binary interaction matrix between drugs and targets, in which each entry indicates whether the interaction between the corresponding drug and target is known or not. In contrast, Kinase contains continuous values of binding affinity for drugtarget pairs. In order to produce a binary interaction matrix, we used the same cutoff threshold as Pahikkala et al. [37] . Drug-to-drug similarities were computed based on the chemical structure of the compound via the SIMCOMP algorithm (GPCR, IC, NR and E datasets) or via the 2D Tanimoto coefficients (Kinase dataset). Target-to-target similarities were computed as the normalized Smith-Waterman score of amino acid sequences of target proteins.
To verify the proposed novel DTIs predicted by the proposed methods, we also constructed the dataset of recently confirmed DTIs on the same sets of drugs and targets as in the original four dataset by Yamanishi et al. [24] . The dataset was constructed by collecting the drugs' and targets' profiles from up-to-date versions of KEGG [38] , DrugBank [39] and
Matador [40] databases and parsing the verified DTIs. This dataset is available in supplementary materials. Table 1 contains some basic statistics of both original and extended datasets.
Basic Notation and Problem Formalization
In this paper, we denote the set of drugs as = { 1 , … , } and the set of targets as = { 1 , … , }, where and are the number of drugs and targets respectively. The × matrix represents known drug-target interactions. is a binary matrix with entries , = 1 denoting that a drug has been experimentally verified to interact with a target , otherwise: , = 0. The matrix ∈ ℝ × represents drug similarity. Each element , contains the similarity between drugs and . Analogically, the matrix ∈ ℝ × represents target similarity.
We further define sets of novel drugs and targets as the drugs (targets) without any
Matrix factorization methods aim to map both drugs and targets into a shared latent space, where denotes its dimension (number of latent factors), ∈ ℝ denotes the latent factors of drug and ∈ ℝ denotes the latent factors of target . We further define ∈ ℝ × as the matrix of all drugs' latent factors and ∈ ℝ × as the matrix of all targets' latent factors. The predicted probability of interaction ̂, between drug and target is defined as the dot product of its latent factors ̂, ≔ × , thus the matrix of predicted DTIs ̂ can be inferred as ̂= . We further define the per-drug training set as the set of triples
We consider the problem of DTI prediction from the perspective of drug-centric repositioning scenario. Thus, the objective for the DTI prediction method is as follows:
 For arbitrary fixed drug ∈ , provide total ordering of all considered targets < such that top-ranked targets should interact with the drug with the highest probability.
Bayesian Personalized Ranking Matrix Factorization
In this section we describe the BPR method [34] in the context of DTI prediction. BPR aims to optimize per-drug ranking by reducing it to pairwise classification of interacting and non-interacting targets. Optimization criterion is based on correctness of the pairwise classification and maximized via stochastic gradient descend with bootstrap sampling of training points.
More specifically, the Bayesian formulation of finding correct per-drug ranking of all targets ∈ is to maximize posterior probability:
where Θ represents parameters of matrix factorization. The > is desired, but latent ordering, specific for the drug . BPR method further assumes independency of drugs on each other, independency of ordering pairs of targets on any other pairs, totality and antisymmetry of the ordering. Hence, the drug-specific likelihood function (Θ | > ) can be combined for all drugs as follows:
The individual probability that drug interacts with target rather than with is defined as follows:
where is the logistic sigmoid function ( ) ≔ 1/(1 + − ) and ̂, , (Θ) is a real-valued evaluation function of the underlying model, capturing the relationship between drug , target and target . For matrix factorization, the natural definition of ̂, , is to substract predicted ratings of known and unknown interaction: ̂, , ≔̂, −̂, and model parameters Θ are the latent factors of drugs and targets: Θ = ( , ). BPR method further assumes the prior density of model parameters to be of normal distribution with zero mean
, where is a model specific regularization parameter. Thus the optimization criterion BPR-OPT can be derived as follows:
Modifying BPR for DTI prediction
Although there is a certain level of similarity between DTI prediction problem and the personalized ranking in preference learning, these problems differ in several important aspects. First, some well-founded metrics of drugs' and targets' similarity were proposed (e.g., [24, 36] ) and the underlined latent space model should reflect those similarities. Furthermore, DTI prediction methods should be able to provide predictions also for drugs and targets without any known interactions. The rest of this section provides insight on how we extended BPR in order to comply with these requirements.
Content Alignment for BPR
We note that drugs and targets are not independent and we can define similarity matrices , describing relations between drugs and targets respectively. The aim of content alignment is to reflect the aforementioned similarities during the matrix decomposition process. Therefore, we extend the BPR optimization criterion by an additive regularization based on the similarity of objects (drugs and targets) and its latent factors. Using the work of Nguyen and Zhu [41] , we implemented a regularization based on the squared norm of the latent factors distance. The regularization was applied on both the drug, the interacting target and the non-interacting target of training set entries ( , , ) ∈ . The optimization term CA for the training set entry ( , , ) ∈ is as follows:
However, our intention is to impose the latent factors' similarity only on highly similar drugs or targets as the large volume of objects with low similarity could significantly bias the results. In order to achieve this, the similarity matrices and were reduced to contain only the top-k most similar neighbors to each drug and target. In order to keep the model simple, we empirically define = 5. This approach is in line with the one used by
Liu et al. [31] and in addition to the performance improvements, it also increases computational efficiency.
Adding Target Bias to BPR
In preference learning, much of the observed variation can be attributed to the latent effects associated solely with the objects, independent of their interactions [42] . Such effects may be captured by bias terms in the prediction model. In DTI datasets some targets have higher number of interactions than others, thus their probability to interact with a drug is higher in general. To cope with this effect, we incorporated target bias into the optimization criteria and DTI prediction. Denoting the bias of target as and the vector of all biases as , the biased optimization criteria BPR-OPT bias and biased DTI prediction ̂, , can be defined as follows.
DTI Prediction for Novel Drugs and Targets
In case of the novel drugs ∈ and targets ∈ with no known interaction, BPR method can only learn their latent factors through negative examples (unknown DTIs).
However, as those DTIs are not confirmed to be negative (in fact, some of them are actually confirmed DTIs, hidden during the training phase), learning from negative-only information inevitably corrupts the model. In order to overcome this problem, we use neighborhood-based approach for novel drugs and targets. After the training phase, latent factors and biases of each novel drug ∈ and novel target ∈ are approximated by the linear combination of its neighbors' latent factors:
BRDTI Method
To sum up, we propose Bayesian Personalized Ranking Prediction of Drug-Target Interactions (BRDTI) method, which is assembled as follows. The original BPR method's regularization is extended with content alignment CA, biased DTI prediction formula ̂, , is used and in case of novel drug or target, neighborhood-based approximation is applied.
The final BRDTI optimization criterion is:
Bootstrapped stochastic gradient ascend is used to maximize the BRDTI-OPT criterion.
Update rules for each parameter are as follows:
where = ( +̂, − ( +̂, )) and hyperparameters , and are learning rate, general regularization and content alignment regularization respectively. Algorithm 1 contains pseudocode of the proposed method. 
FUNCTION OPTIMIZE_BRDTI
Normalized Discounted Cumulative Gain
As we consider DTI prediction to be a per-drug ranking problem, we evaluate ranked lists for each drug separately and use normalized discounted cumulative gain (nDCG) as evaluation metric, which was shown to be the best graded relevance ranking metric with respect to the stability and sensitivity [43] . For the ranked list p DCG is calculated as follows: There are several advantages of using nDCG as evaluation metric for DTI.
1) Each position in the ranked list is associated with a gradually decreasing weight, reflecting the potential impact of relevant object placed on the respective position. This reflects well the drug repositioning scenario, where confirmation of each further candidate DTI is both temporally and monetarily expensive.
2) nDCG may use graded relevance characteristics, allowing to distinguish DTIs with higher potential impact from the others.
3) nDCG can be naturally truncated to consider only top-k objects and thus reflect the scenario, where exhaustive validation of all proposed DTIs is not possible and we can only verify several predicted DTIs.
Evaluation and Results
Similarly as in previous studies (e.g., [30] ), the performance of BRDTI method was evaluated via five times repeated 10-fold cross-validation (5x10-fold CV). In each of the five repetitions, we randomly assign known DTIs to one out of ten splits. Then, we run 10-fold CV. In each of the ten iterations of 10-fold CV, a different split is used as test set, while the remaining splits are used as training set (matrix R). We adopted normalized discounted cumulative gain (nDCG) as an evaluation metric and evaluate the results in a per-drug fashion. We report the average nDCG values over all drugs and CV runs and denote it as per-drug nDCG. In order to remain comparable with previous studies, we also provide results in terms of AUC.
The proposed BRDTI method was compared with four state of the art approaches: BLM-NII [25] , WNN-GIP [28] , NetLapRLS [26] and CMF [30] . Grid-search was used to tune methods' hyperparameters, details can be found in supplementary materials. Table 2 shows results in terms of nDCG. BRDTI method achieved the best results on GPCR, Nuclear Receptors and Enzymes datasets and second best (without significant difference) on Ion Channel and Kinase datasets. In pairwise comparison (paired t-test, < 0.05), BRDTI significantly outperformed its competitors in 17 out of 20 cases w.r.t. nDCG. Table 3 shows the results in terms of AUC. BRDTI achieved the best results w.r.t. AUC except on Kinase dataset, where it ended second. BRDTI significantly outperformed its competitors in 18 out of 20 cases w.r.t. AUC. The performance of the methods is further illustrated in Figure 1 by ROC curves on the GPCR dataset. Other datasets exhibited similar ROC curves and thus we omit them. We can conclude that BRDTI can be successfully applied to predict DTIs for existing drugs. Table 4 Described variants represent design choices made during BRDTI assembling and the results support our decisions as BRDTI significantly outperformed the other approaches.
Results
Predicting Recently Confirmed DTI
In this section, we illustrate that BRDTI not only achieves high accuracy in terms of nDCG and AUC, but its predictions are biologically feasible as well. Note that the drug-target interactions contained in the Enzyme, Ion Channel, GPCR and NR datasets were extracted several years ago and they have been kept unchanged to allow comparison between DTI prediction methods. Further interactions between the same drugs and targets have been confirmed recently (i.e., after the publication of the original datasets). Our intention is to demonstrate that BRDTI is a viable method for disclosing unknown interactions as it is capable of predicting the aforementioned recently confirmed interactions by learning from those interactions that were known previously (i.e., from interactions contained in the original datasets). Therefore, we trained BRDTI and its competitors using all the interactions of the original datasets, predict per-drug ranking of all unknown drug-target pairs and compare the predictions with the list of recently confirmed DTIs. Figure 2 illustrates the approach.
We validated predicted interactions in up-to-date versions of KEGG, DrugBank and Matador databases. Overall, 2514 recently confirmed DTI were found. However, for a substantial portion of drugs (61%), there were no recently confirmed interactions and thus they were excluded. Table 5 depicts the results w.r.t. top-10 considered targets for each drug. BRDTI performs the best, closely followed by NetLapRLS. Performance of CMF is considerably lower compared to the results in the original datasets.
Drug Repurposing Based on the DTI Predictions
Next, we will illustrate that the predictions of BRDTI may contribute to promising thera- Finally, we point out that Lipoyltransferase 1 gene (LIPT1) defects cause Leigh disease [48] and, in case of severe defects, fatal lactic acidosis [49, 50] . We hypothesize that in some cases of LIPT mutations, an agonist could help to increase enzymatic activity. We predicted Biotin (D00029) to interact with LIPT1 (hsa51601). Biotin is transported across the blood-brain barrier and it was proposed as a treatment of multiple sclerosis previously [51] . Based on our aforementioned prediction, it would be interesting to examine Biotin as a potential therapy for LIPT1 mutations as well.
Discussion
This paper considers the problem of DTI predictions for drug-centric repositioning approach. We pointed out that such an approach may benefit from carefully optimized ranking of possible targets for a specific drug and presented a novel DTI prediction method, However, results of recently confirmed DTI prediction also illustrate that there is still room for improvement as some of the new interactions were neglected by all evaluated methods.
This can be illustrated on the example of Haldol (D00136), for which 10 new interactions are known, however none of the evaluated method listed any of these interactions into the top-10 predictions. As there were neither strong similarities between original and new targets, nor substantial collaborative information through similar drugs, it is important to define and incorporate further concepts of similarity into the prediction models (e.g., [52, 53] ).
The full list of DTIs predicted by BRDTI method can be found in supplementary materials.
Also, note that BRDTI source codes can be easily modified to run BRDTI on further datasets, see also the instructions in the supplementary materials.
Success of BRDTI method encourages us to test further ranking methods, e.g., RankALS [35] for DTI prediction task. Furthermore, it would be interesting to develop DTI prediction techniques that are able to take specific conditions (temperature, cell type or subtype, presence or absence of a disease, etc.) into account and make DTI predictions for those conditions. For example, Wenzel et al. [54] reported that their bimetallic cytotoxic complexes were shown to be easily taken up by cancer cells at 37 °C, whereas experiments at 4 °C showed no uptake. Incorporation of the aforementioned conditions into DTI prediction methods, in order to allow for more specific predictions, is left for future work. 
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